AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
2004 FEB 5 - (NewsRx.com & NewsRx.net) -- Andrx Corporation (ADRX) announced that the U.S. Food and Drug Administration (FDA) has tentatively approved the company's Abbreviated New Drug Application (ANDA) for Ortho Tri-Cyclen (norgestimate/ethinyl estradiol) tablets, an Ortho-McNeil Pharmaceutical, Inc., oral contraceptive product.
The Andrx ANDA is for 0.18 mg/0.035 mg, 0.215 mg/0.035 mg, and 0.25 mg/0.035 mg strengths, packaged in 28-day cycle regimens. According to the FDA's letter, pediatric exclusivity was granted for this product, thereby extending the effective expiration date of the patents pertaining to this product until March 26, 2004.
The company has received inquiries regarding the January 7, 2004, update of new drug approvals issued by Center for Drug ...